Molnupiravir (EIDD-2801/MK-4482) Supply Agreement for Pandemic Purposes
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Procedure | limited |
| OCID | ocds-h6vhtk-02f5dc |
Awards (2)
This procurement was awarded to 2 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Merck Sharpe and Dohme (UK) Limited | · | · | active |
| Merck Sharpe & Dohme (UK) Limited | £1 | 12 Oct 2021 | active |
description
Vaccines have been shown to be highly effective in the fight against COVID-19, to date. However, there is a cohort of individuals who either cannot take the vaccine or for whom it is ineffective. There is therefore an urgent need to find an effective alternative. So far there are no primary care antiviral drugs that can be easily dispensed specifically to treat SARS-CoV-2 and prevent its transmission in the community. This agreement is for the procurement of 480,000 units of Molnupiravir (EIDD-2801/MK-4482). It is one of the first oral and direct-acting antiviral drugs globally and the first to receive regulatory approval and is part of the UK’s multi-layered approach to COVID-19.
notice history
2 notices published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 11 Nov 2021 | Contract award notice (F03) | Earlier regulations | 028271-2021 |
| 18 Nov 2021 | Award (award) | · | cd40a4e6-f80b-4a30-986b-7bba753e2710-486698 |
more from Department of Health and Social Care
- DHSC: Fin: Interim Senior Financial Accountant · £94,250 · 29 Jul 2026
- DHSC: Fin: Interim Financial Accountant · £66,400 · 29 Jul 2026
- DHSC Sinogo claim legal support · £100,000 · 22 Jul 2026
- National Institute for Health and Care Research (NIHR) pre-action letter advice · £80,000 · 22 Jul 2026
- DHSC: ASC: Waves 3 – 5 of the Adult Social Care Workforce Employee Survey · 15 Jul 2026
- Hugh's Report - MH Impact of Life-Threatening Child Illness on Families 2026 · 26 Jun 2026
- Library Mgmt and Enquiry System, E-Archive · £22,578 · 22 Jun 2026
- DHSC: Leeds Maternity Review legal services · £432,000 · 22 Jun 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.